Method of using estrogen-related receptor alpha (ERRα) status to determine prognosis, treatment strategy and predisposition to breast cancer, and method of using ERRα as a therapeutic target for the treatment of breast cancer
US7541141B2 · kind B2 · utility
0Cited by
1References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 5, 2002 |
| Grant date | Jun 2, 2009 |
| Priority date | — |
| Expiry date | Aug 3, 2025 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides that ERRα is a breast cancer biomarker of clinical course and treatment sensitivity and, itself, a target for breast cancer treatment. A high ERRα level in breast cancer indicates poor prognosis. Analyzing ERRα expression level along with the status of ERα and ErbB2 can help breast cancer patients make treatment choices. Furthermore, breast cancer can be treated by modulating ERRα activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.